Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[WT1 Gene and Leukemia]

Rong Wang1

  • 1Department of Hematology, College of Medicine, Jinan University, Guangzhou 510632, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|February 13, 2003
PubMed
Summary
This summary is machine-generated.

The WT1 gene, typically a tumor suppressor, acts oncogenically in leukemia. Suppressing WT1 inhibits cancer cell growth and promotes apoptosis, indicating a complex role in hematopoietic progenitor cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationships between hemorrhage, angioarchitectural factors and collagen of arteriovenous malformations.

Neuroscience bulletin·2012
Same author

Inhibitory effects of salvianolic acid B on CCl(4)-induced hepatic fibrosis through regulating NF-κB/IκBα signaling.

Journal of ethnopharmacology·2012
Same author

Combined organic-inorganic fouling of forward osmosis hollow fiber membranes.

Water research·2012
Same author

Expression of the human glucokinase gene: important roles of the 5' flanking and intron 1 sequences.

PloS one·2012
Same author

Long term outcome after conservative and surgical treatment of haemorrhagic moyamoya disease.

Journal of neurology, neurosurgery, and psychiatry·2012
Same author

A role for low-abundance miRNAs in colon cancer: the miR-206/Krüppel-like factor 4 (KLF4) axis.

Clinical epigenetics·2012
Same journal

[Research Progress on the Bone Marrow Microenvironment in Beta-Thalassemia --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of CAR-T Cell Therapy in Autoimmune Diseases --Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress of Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Research Progress in Venetoclax-Based Combination Therapy in Acute Myeloid Leukaemia--Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Advances in the Treatment of Acute Myeloid Leukemia with <i>TP53</i> Mutations-Review].

Zhongguo shi yan xue ye xue za zhi·2026
Same journal

[Analysis of Risk Factors and Clinical Characteristics of Early Death in Patients with Hemophagocytic Syndrome].

Zhongguo shi yan xue ye xue za zhi·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • The Wilms tumor 1 (WT1) gene is traditionally recognized as a tumor suppressor, regulating growth factor and receptor gene transcription.
  • However, elevated WT1 expression in human leukemic cells is linked to poor prognosis, suggesting a contradictory role.

Purpose of the Study:

  • To investigate the dualistic function of the WT1 gene in hematopoietic progenitor cells and its potential oncogenic role in leukemia.

Main Methods:

  • Utilized WT1 anti-sense oligonucleotides to suppress WT1 expression in leukemic cells.
  • Transfected myeloid progenitor cells with the wild-type WT1 gene to study its constitutive effects.

Main Results:

  • Suppression of WT1 expression led to inhibited proliferation and induced apoptosis in leukemic cells.

Related Experiment Videos

  • Constitutive WT1 expression in myeloid progenitor cells enhanced G-CSF-mediated proliferation but suppressed differentiation.

    • Conclusions:

    • WT1 exhibits an oncogenic function in hematopoietic progenitor cells, contrary to its established tumor suppressor role.
    • Targeting WT1 may offer a therapeutic strategy for certain leukemias.